A peer reviewed study led by Proteome Sciences plc ('Proteome Sciences'), in conjunction with a group of highly respected universities and hospitals, demonstrates the ability of an innovative mass spectrometry (MS) workflow to dramatically improve the ability to detect tau-derived peptides that are directly related to human Alzheimer's pathology as early stage biomarkers of the disease.

Published on-line in the Journal of Alzheimer's Disease , the study describes the application of the workflow, TMTcalibrator™, for high-sensitivity detection of phosphorylated tau and other disease- relevant biomarkers of Alzheimer's disease (AD) in cerebrospinal fluid (CSF).

The TMTcalibrator™ workflow combines analysis of diseased tissue and body fluids to enhance mass spectrometric detection of tissue-derived biomarkers at unparalleled levels of sensitivity.

Demonstrating this, the study, the first to be published using TMTcalibrator™, reports the detection of 47 tau phosphopeptides covering 31 clinically-relevant phosphorylation sites. In total 76.8% coverage of human tau in CSF was obtained. Read More.

Proteome Sciences plc published this content on 22 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 September 2016 15:16:05 UTC.

Original documenthttp://www.proteomics.com/news-and-events/news/post/spectrometry-technique-dramatically-enhances-detection-of-key-early-stage-alzheimer-s-biomarkers

Public permalinkhttp://www.publicnow.com/view/3BB987B3AFC68B024B693E3A6C2646C20C603FF3